bioRxiv · 10.1101/2021.08.23.457419
Discovery of Antiviral Cyclic Peptides Targeting the Main Protease of SARS-CoV-2 via mRNA Display
Abstract
Antivirals that specifically target SARS-CoV-2 are needed to control the COVID-19 pandemic. The main protease (Mpro) is essential for SARS-CoV-2 replication and is an attractive target for antiviral development. Here we report the use of the Random nonstandard Peptide Integrated Discovery (RaPID) mRNA display on a chemically cross-linked SARS-CoV-2 Mpro dimer, which yielded several high-affinity thioether-linked cyclic peptide inhibitors of the protease. Structural analysis of Mpro complexed with a selenoether analogue of the highest-affinity peptide revealed key binding interactions, including glutamine and leucine residues in sites S1 and S2, respectively, and a binding epitope straddling both protein chains in the physiological dimer. Several of these Mpro peptide inhibitors possessed antiviral activity against SARS-CoV-2 in vitro with EC50 values in the low micromolar range. These cyclic peptides serve as a foundation for the development of much needed antivirals that specifically target SARS-CoV-2.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Johansen-Leete, J., Ullrich, S., Fry, S., Frkic, R., Bedding, M., Aggarwal, A., Ashhurst, A., Ekanayake, K., Mahawaththa, M., Sasi, V., Passioura, T., Larance, M., Otting, G., Turville, S. G., Jackson, C. J., Nitsche, C., Payne, R. J.. 2021-08-24. Discovery of Antiviral Cyclic Peptides Targeting the Main Protease of SARS-CoV-2 via mRNA Display. https://doi.org/10.1101/2021.08.23.457419
Cite the original work for its findings. Save a collection to share your selection of sources.